ライフサイエンスコーパス: tumor rejection antigen

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 oncofetal antigen can serve as an effective tumor rejection antigen.

2 trated that this epitope represents a potent tumor rejection antigen.

3 tify the human IL-13Ralpha2 chain as a novel tumor rejection antigen.

4 stage-specific embryonic antigen 4 (SSEA-4), tumor rejection antigen 1-60 (TRA 1-60), and tumor rejec

5 tumor rejection antigen 1-60 (TRA 1-60), and tumor rejection antigen 1-81 (TRA 1-81) (traditional mar

6 e shows that it is highly similar to gp96, a tumor rejection antigen-1, and contains an endoplasmic r

7 munotherapy depends on the identification of tumor-rejection antigens (Ags).

8 attractive candidate for a broadly expressed tumor rejection antigen because telomerase is silent in

9 resents the first demonstration that a human tumor rejection antigen can be generated from a normal c

10 mutated tumor antigen to be identified, is a tumor rejection antigen for J558 plasmacytoma in mice wi

11 Thus, P1A is not a necessary tumor rejection antigen for the J558 tumor cells.

12 small number of cancers where candidates for tumor rejection antigens have been identified.

13 -associated fibroblasts, could function as a tumor rejection antigen in a broad range of cancers.

14 mor line serves as an immunization-dependent tumor rejection antigen in normal syngeneic mice.

15 The onconeural antigens appear to serve as tumor rejection antigens in the paraneoplastic neurologi

16 ity to neu, and possibly to similar putative tumor-rejection antigens, may lead to more potent in viv

17 ulates that peptide mimetics of glycosylated tumor rejection antigens might be further developed for

18 and their possible coexistence as potential tumor rejection antigens on associated tumors.

19 accines will require identifying appropriate tumor-rejection antigens; optimizing the interactions of

20 ransgenic CD8+ T cells against the unmutated tumor rejection antigen P1A to analyze whether this mAb

21 ith cancer, and a 24-amino acid product as a tumor rejection antigen recognized by T cells.

22 libraries can therefore be used to identify tumor rejection antigens that can cooperate to induce an

23 Therefore, even though P1A can be a tumor rejection antigen, the effector function of P1A-sp

24 n of tumor-associated antigens (TAAs) and/or tumor rejection antigens (TRAs).

25 of Tms requires designing vaccines based on tumor rejection antigens, which are often not available

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。